Paul Choi
Stock Analyst at Goldman Sachs
(4.38)
# 1,265
Out of 4,630 analysts
372
Total ratings
55.7%
Success rate
9.5%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintained: Buy | n/a | $76.76 | - | 11 | Aug 7, 2026 | |
| EXEL Exelixis | Maintained: Buy | $64 | $54.07 | +18.37% | 10 | Aug 5, 2026 | |
| URGN UroGen Pharma | Maintained: Hold | $44 → $48 | $46.96 | +2.21% | 25 | Aug 5, 2026 | |
| PTCT PTC Therapeutics | Maintained: Sell | $55 → $70 | $73.31 | -4.52% | 26 | Jul 30, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintained: Buy | $75 → $90 | $76.06 | +18.33% | 20 | Jul 30, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $300 | $255.41 | +17.46% | 27 | Jul 27, 2026 | |
| HCM HUTCHMED (China) | Rated: Hold | $19 → $14 | $12.53 | +11.73% | 20 | Jul 23, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Hold | $20 → $32 | $43.52 | -26.47% | 3 | Jun 17, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $95 → $90 | $32.89 | +173.64% | 4 | Jun 5, 2026 | |
| RGNX REGENXBIO | Maintained: Hold | $12 → $10 | $10.72 | -6.72% | 11 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $13.92 | +187.36% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $8.75 | -31.43% | 8 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $112 → $116 | $84.48 | +37.31% | 35 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $77 → $94 | $100.95 | -6.88% | 5 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $8.82 | +138.10% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $8.55 | - | 18 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $63.36 | +18.37% | 12 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 | $14.36 | -16.43% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $0.5 | $0.178 | +180.90% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.10 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.27 | n/a | 25 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.19 | n/a | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $63.81 | n/a | 1 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $133.33 | $19.48 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $6.07 | n/a | 5 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $3.5 | $6.16 | n/a | 4 | Apr 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $7 | $8.91 | n/a | 8 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $9 | $13.25 | n/a | 5 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $108.92 | n/a | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $5.55 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $150,000.00 | n/a | 2 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 | $163.41 | n/a | 4 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $18 → $20 | $76.48 | n/a | 5 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $135 → $165 | $120.56 | n/a | 2 | Nov 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $1,185.71 | n/a | 1 | Apr 7, 2017 |
Cytokinetics
Aug 7, 2026
Maintained: Buy
Price Target: n/a
Current: $76.76
Upside: -
Exelixis
Aug 5, 2026
Maintained: Buy
Price Target: $64
Current: $54.07
Upside: +18.37%
UroGen Pharma
Aug 5, 2026
Maintained: Hold
Price Target: $44 → $48
Current: $46.96
Upside: +2.21%
PTC Therapeutics
Jul 30, 2026
Maintained: Sell
Price Target: $55 → $70
Current: $73.31
Upside: -4.52%
Kiniksa Pharmaceuticals International,
Jul 30, 2026
Maintained: Buy
Price Target: $75 → $90
Current: $76.06
Upside: +18.33%
Ascendis Pharma
Jul 27, 2026
Maintained: Buy
Price Target: $300
Current: $255.41
Upside: +17.46%
HUTCHMED (China)
Jul 23, 2026
Rated: Hold
Price Target: $19 → $14
Current: $12.53
Upside: +11.73%
Edgewise Therapeutics
Jun 17, 2026
Rated: Hold
Price Target: $20 → $32
Current: $43.52
Upside: -26.47%
Vera Therapeutics
Jun 5, 2026
Maintained: Buy
Price Target: $95 → $90
Current: $32.89
Upside: +173.64%
REGENXBIO
May 14, 2026
Maintained: Hold
Price Target: $12 → $10
Current: $10.72
Upside: -6.72%
May 14, 2026
Maintained: Buy
Price Target: $40
Current: $13.92
Upside: +187.36%
May 12, 2026
Maintained: Sell
Price Target: $6
Current: $8.75
Upside: -31.43%
May 8, 2026
Maintained: Buy
Price Target: $112 → $116
Current: $84.48
Upside: +37.31%
May 7, 2026
Maintained: Hold
Price Target: $77 → $94
Current: $100.95
Upside: -6.88%
May 6, 2026
Maintained: Buy
Price Target: $21
Current: $8.82
Upside: +138.10%
Apr 30, 2026
Maintained: Hold
Price Target: n/a
Current: $8.55
Upside: -
Mar 10, 2026
Maintained: Buy
Price Target: $75
Current: $63.36
Upside: +18.37%
Feb 25, 2026
Maintained: Sell
Price Target: $12
Current: $14.36
Upside: -16.43%
Feb 24, 2026
Downgraded: Hold
Price Target: $8 → $0.5
Current: $0.178
Upside: +180.90%
Feb 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $5.10
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.27
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.19
Upside: n/a
Jun 4, 2024
Maintained: Buy
Price Target: n/a
Current: $63.81
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: $133.33
Current: $19.48
Upside: n/a
Jun 28, 2023
Maintained: Buy
Price Target: $19
Current: $6.07
Upside: n/a
Apr 3, 2022
Downgraded: Hold
Price Target: $25 → $3.5
Current: $6.16
Upside: n/a
Nov 5, 2021
Maintained: Hold
Price Target: $8 → $7
Current: $8.91
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: $12 → $9
Current: $13.25
Upside: n/a
Mar 4, 2021
Maintained: Buy
Price Target: $15 → $17
Current: $108.92
Upside: n/a
Nov 9, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $5.55
Upside: n/a
Aug 24, 2020
Maintained: Sell
Price Target: n/a
Current: $150,000.00
Upside: n/a
Jun 29, 2020
Downgraded: Hold
Price Target: $135
Current: $163.41
Upside: n/a
Mar 30, 2020
Upgraded: Hold
Price Target: $18 → $20
Current: $76.48
Upside: n/a
Nov 1, 2017
Maintained: Buy
Price Target: $135 → $165
Current: $120.56
Upside: n/a
Apr 7, 2017
Reiterated: Buy
Price Target: $90
Current: $1,185.71
Upside: n/a